Budget impact model for ranolazine in chronic stable angina
1
Public health medicine, Universiti kebangsaan malaysia, Kuala lumpur, Malaysia
2
Public health unit, Universiti sains islam malaysia, Negeri sembilan, Malaysia
3
Cardiology department, Hospital canselor tuanku muhriz, Kuala Lumpur, Malaysia
4
Pharmacy department, Hospital canselor tuanku muhriz, Kuala Lumpur, Malaysia
Popul. Med. 2026;8(Supplement Supplement 1):A1735
ABSTRACT
ABSTRACT:
Budget Impact Model for Ranolazine in Chronic Stable Angina
BACKGROUND:
Chronic Stable Angina (CSA) is a significant public health issue in Malaysia, affecting an estimated 1.46 million adults. This prevalence strains the public healthcare system, impacting patients' quality of life and resource allocation. Budget impact analysis (BIA) evaluates the economic effects of adding Ranolazine to the Ministry of Health (MOH) Malaysia formulary.
METHODS:
The BIA model assesses the financial impact of adding Ranolazine to standard CSA therapy over five years from MOH Malaysia’s perspective. It compares current standard therapy with a scenario where Ranolazine is available to eligible patients inadequately controlled or intolerant to first-line treatments. The analysis uses local epidemiological data, published literature, and expert input to estimate direct medical costs, including drug prices, hospitalisation, outpatient visits, procedures, and rescue medication. Clinical efficacy and resource use estimates are based on local expert consensus. The model reports annual and cumulative costs for both scenarios, with the difference as the net budget impact.
RESULTS:
While Ranolazine is expected to increase drug expenditures over five years, its clinical benefits are projected to generate substantial cost savings by reducing high-cost resource use. These savings are expected to increase steadily, resulting in nearly 5% net budget reduction compared to current treatment options. The main drivers of these savings include fewer hospital admissions, reduced need for cardiac revascularisation procedures such as coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), and decreased reliance on rescue medications.
CONCLUSIONS:
The BIA provides clear estimates of budgetary changes and highlights potential savings for the public health system if Ranolazine is included in the formulary. The framework offers a transparent and adaptable basis for policy discussions and future local evaluations. Further locally generated real-world evidence is needed to strengthen future evaluations.
Budget Impact Model for Ranolazine in Chronic Stable Angina
BACKGROUND:
Chronic Stable Angina (CSA) is a significant public health issue in Malaysia, affecting an estimated 1.46 million adults. This prevalence strains the public healthcare system, impacting patients' quality of life and resource allocation. Budget impact analysis (BIA) evaluates the economic effects of adding Ranolazine to the Ministry of Health (MOH) Malaysia formulary.
METHODS:
The BIA model assesses the financial impact of adding Ranolazine to standard CSA therapy over five years from MOH Malaysia’s perspective. It compares current standard therapy with a scenario where Ranolazine is available to eligible patients inadequately controlled or intolerant to first-line treatments. The analysis uses local epidemiological data, published literature, and expert input to estimate direct medical costs, including drug prices, hospitalisation, outpatient visits, procedures, and rescue medication. Clinical efficacy and resource use estimates are based on local expert consensus. The model reports annual and cumulative costs for both scenarios, with the difference as the net budget impact.
RESULTS:
While Ranolazine is expected to increase drug expenditures over five years, its clinical benefits are projected to generate substantial cost savings by reducing high-cost resource use. These savings are expected to increase steadily, resulting in nearly 5% net budget reduction compared to current treatment options. The main drivers of these savings include fewer hospital admissions, reduced need for cardiac revascularisation procedures such as coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), and decreased reliance on rescue medications.
CONCLUSIONS:
The BIA provides clear estimates of budgetary changes and highlights potential savings for the public health system if Ranolazine is included in the formulary. The framework offers a transparent and adaptable basis for policy discussions and future local evaluations. Further locally generated real-world evidence is needed to strengthen future evaluations.
| eISSN: | 2654-1459 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
